See the published version of this article at Health and Quality of Life Outcomes.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Patients’ confidence in treatment decisions for early stage non-small cell lung cancer (NSCLC)
Cecilia Pompili
Leeds Institute of Cancer and Pathology
Corresponding Author
ORCiD: https://orcid.org/0000-0001-6746-5441
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published version at Health and Quality of Life Outcomes.
Background In early-stage Non-Small Cell Lung Cancer (NSCLC) patients, little is known about how to measure patient participation in Shared-Decision Making (SDM). We examined the psychometric properties and clinical acceptability of the Decision Self-Efficacy scale (DSE) in a cohort of patients undergoing to Stereotactic Ablative Radiotherapy (SABR) or Video-assisted Thoracoscopic Surgery (VATS) to capture patient involvement in treatment decisions.
Methods In the context of a prospective longitudinal study (Life after Lung Cancer-LiLAC) involving 244 patients with early-stage NSCLC, 158 (64.7%) patients completed the DSE either on paper or electronically online prior to treatment with SABR or VATS pulmonary resection. DSE psychometric properties were examined using: principal components analysis of item properties and internal structure, and internal construct validity; we also performed a sensitivity analysis according to Eastern Cooperative Oncology Group Performance Status (ECOG PS), gender, age and treatment received (VATS or SABR) difference.
Results Exploratory factor analysis using polychoric correlations substantiated that the 11 item DSE is one scale accounting for 81% of the variance. We calculated a value of 0.96 for Cronbach’s alpha for the total DSE score. DSE scores did not differ by gender ( p =0.37), between the two treatment groups (p=0.09) and between younger and older patients ( p =0.4). However, patients with an ECOG PS >1 have a DSE mean of 73.8 (SD 26) compared to patients with a PS 0-1 who have a DSE mean of 85.8 (SD 20.3 p =0.002).
Conclusion Findings provide preliminary evidence for the reliability and validity of the DSE questionnaire in this population. However, future studies are warranted to identify the most appropriate SDM tool for clinical practice in the lung cancer treatment field.
Keywords
Shared decision making, informed decision making, self-efficacy, lung cancer, radiotherapy, surgery
This is a list of supplementary files associated with this preprint. Click to download.
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
Version 2
Posted 18 May, 2020
Published
On 18 Jul, 2020
No community comments so far
Editorial decision: Accept
On 30 Jun, 2020
Review #2 received
Received 27 Jun, 2020
Review #1 received
Received 25 Jun, 2020
Reviewer #2 agreed
On 03 Jun, 2020
Reviewer #1 agreed
On 30 May, 2020
Reviewers invited
Invitations sent on 30 May, 2020
Editor assigned
On 07 May, 2020
Submission checks complete
On 06 May, 2020
Editor invited
On 06 May, 2020
No comments provided
Editorial decision: Major Revision
On 24 Mar, 2020
Review #1 received
Received 12 Feb, 2020
Review #2 received
Received 09 Feb, 2020
Reviewer #2 agreed
On 25 Jan, 2020
Reviewer #1 agreed
On 23 Jan, 2020
Reviewers invited
Invitations sent on 22 Jan, 2020
Editor assigned
On 20 Jan, 2020
Submission checks complete
On 19 Jan, 2020
Editor invited
On 19 Jan, 2020
First submitted
On 17 Jan, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This preprint is under consideration at Health and Quality of Life Outcomes. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Patients’ confidence in treatment decisions for early stage non-small cell lung cancer (NSCLC)
Cecilia Pompili
Leeds Institute of Cancer and Pathology
Corresponding Author
ORCiD: https://orcid.org/0000-0001-6746-5441
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
Version 2
Posted 18 May, 2020
Published
On 18 Jul, 2020
No community comments so far
Editorial decision: Accept
On 30 Jun, 2020
Review #2 received
Received 27 Jun, 2020
Review #1 received
Received 25 Jun, 2020
Reviewer #2 agreed
On 03 Jun, 2020
Reviewer #1 agreed
On 30 May, 2020
Reviewers invited
Invitations sent on 30 May, 2020
Editor assigned
On 07 May, 2020
Submission checks complete
On 06 May, 2020
Editor invited
On 06 May, 2020
No comments provided
Editorial decision: Major Revision
On 24 Mar, 2020
Review #1 received
Received 12 Feb, 2020
Review #2 received
Received 09 Feb, 2020
Reviewer #2 agreed
On 25 Jan, 2020
Reviewer #1 agreed
On 23 Jan, 2020
Reviewers invited
Invitations sent on 22 Jan, 2020
Editor assigned
On 20 Jan, 2020
Submission checks complete
On 19 Jan, 2020
Editor invited
On 19 Jan, 2020
First submitted
On 17 Jan, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published version at Health and Quality of Life Outcomes.
Background In early-stage Non-Small Cell Lung Cancer (NSCLC) patients, little is known about how to measure patient participation in Shared-Decision Making (SDM). We examined the psychometric properties and clinical acceptability of the Decision Self-Efficacy scale (DSE) in a cohort of patients undergoing to Stereotactic Ablative Radiotherapy (SABR) or Video-assisted Thoracoscopic Surgery (VATS) to capture patient involvement in treatment decisions.
Methods In the context of a prospective longitudinal study (Life after Lung Cancer-LiLAC) involving 244 patients with early-stage NSCLC, 158 (64.7%) patients completed the DSE either on paper or electronically online prior to treatment with SABR or VATS pulmonary resection. DSE psychometric properties were examined using: principal components analysis of item properties and internal structure, and internal construct validity; we also performed a sensitivity analysis according to Eastern Cooperative Oncology Group Performance Status (ECOG PS), gender, age and treatment received (VATS or SABR) difference.
Results Exploratory factor analysis using polychoric correlations substantiated that the 11 item DSE is one scale accounting for 81% of the variance. We calculated a value of 0.96 for Cronbach’s alpha for the total DSE score. DSE scores did not differ by gender ( p =0.37), between the two treatment groups (p=0.09) and between younger and older patients ( p =0.4). However, patients with an ECOG PS >1 have a DSE mean of 73.8 (SD 26) compared to patients with a PS 0-1 who have a DSE mean of 85.8 (SD 20.3 p =0.002).
Conclusion Findings provide preliminary evidence for the reliability and validity of the DSE questionnaire in this population. However, future studies are warranted to identify the most appropriate SDM tool for clinical practice in the lung cancer treatment field.